Melanoma
Oncology 8 original drugsPhase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q3 2026
HBI-8000 in combination with nivolumab
HUYABIO International, LLC.
Estimated · aging NCT04674683
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 80 industry trials with a known mechanism of action.
Programmed Death Receptor-1 Blocking Antibody
38 trials 5 active 7 sponsors
ALK/ROS1/NTRK1/TRKB/TRKC
1 trials 1 active 1 sponsor
CTLA-4-directed Blocking Antibody
16 trials 3 sponsors
Kinase Inhibitor
15 trials 4 sponsors
Programmed Death Ligand-1 Blocker
2 trials 2 sponsors
Azole Antifungal
2 trials 1 sponsor
Lymphocyte Growth Factor
1 trials 1 sponsor
CD30-directed Immunoconjugate
1 trials 1 sponsor
Alkylating Drug
1 trials 1 sponsor
CD25-directed Cytotoxin
1 trials 1 sponsor
Platinum-based Drug
1 trials 1 sponsor
Nuclear Export Inhibitor
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
727 industry-sponsored trials across 318 sponsors
Showing 9 of 9 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Novartis | dabrafenib | — | RECRUITING | 2032-12-28 | NCT03340506 |
| Bristol-Myers Squibb | Nivolumab + Relatlimab | — | NOT YET RECRUITING | 2029-05-26 | NCT07459543 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2024-08-21 | NCT03715205 |
| RECORDATI GROUP | Pasireotide | — | COMPLETED | 2023-07-25 | NCT01794793 |
| Novartis | Nilotinib | — | COMPLETED | 2023-07-07 | NCT01735955 |
| Roche | Zelboraf | Kinase Inhibitor [EPC] | COMPLETED | 2019-05-22 | NCT01898585 |
| Novartis | Aldesleukin | Lymphocyte Growth Factor [EPC] | COMPLETED | 2010-03-28 | NCT00414765 |
| Clinigen, Inc. | High Dose Interleukin-2 | — | TERMINATED | 2015-07 | NCT01856023 |
| Clinigen, Inc. | vemurafenib + HD IL-2 | — | TERMINATED | 2014-11 | NCT01683188 |
Showing 88 of 88 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Regeneron | fianlimab | — | RECRUITING | 2027-03-22 | NCT06246916 |
| mAbxience Research S.L. | MB11 (Proposed Nivolumab Biosimilar) | — | RECRUITING | 2027-04 | NCT07221734 |
| Shanghai Kechow Pharma, Inc. | tunlametinib | — | RECRUITING | 2027-09-22 | NCT06008106 |
| Immunocore Ltd | Brenetafusp | — | RECRUITING | 2027-10-16 | NCT06112314 |
| Aura Biosciences | Bel-sar | — | RECRUITING | 2027-11-15 | NCT06007690 |
| Philogen S.p.A. | Daromun | — | RECRUITING | 2027-12 | NCT03567889 |
| Immatics US, Inc. | IMA203 | — | RECRUITING | 2028-01 | NCT06743126 |
| Immunocore Ltd | Tebentafusp | — | RECRUITING | 2028-03 | NCT05549297 |
| Iovance Biotherapeutics, Inc. | Lifileucel plus Pembrolizumab | — | RECRUITING | 2028-03-01 | NCT05727904 |
| Replimune, Inc. | Vusolimogene Oderparepvec | — | RECRUITING | 2029-01-01 | NCT06264180 |
| Linnaeus Therapeutics, Inc. | LNS8801 | — | RECRUITING | 2029-02 | NCT06624644 |
| Replimune, Inc. | RP2 | — | RECRUITING | 2030-01 | NCT06581406 |
| IDEAYA Biosciences | Darovasertib | — | RECRUITING | 2030-10 | NCT07015190 |
| Eikon Therapeutics | EIK1001 | — | RECRUITING | 2035-12 | NCT06697301 |
| Binhui Biopharmaceutical Co., Ltd. | OH2 | — | RECRUITING | 2026-03 | NCT05868707 |
| HUYABIO International, LLC. | HBI-8000 in combination with nivolumab | — | ACTIVE NOT RECRUITING | 2026-07 | NCT04674683 |
| Biocad | BCD-217 | — | ACTIVE NOT RECRUITING | 2027-01 | NCT05751928 |
| IDEAYA Biosciences | IDE196 | — | ACTIVE NOT RECRUITING | 2027-01-15 | NCT05987332 |
| Pierre Fabre Medicament | Encorafenib and Binimetinib | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT05270044 |
| Amgen | ABP 206 | — | ACTIVE NOT RECRUITING | 2028-01-25 | NCT06054555 |
| Erasca, Inc. | Naporafenib | — | ACTIVE NOT RECRUITING | 2028-04 | NCT06346067 |
| Regeneron | Fianlimab | — | ACTIVE NOT RECRUITING | 2028-05-16 | NCT05608291 |
| Merck | Intismeran autogene | — | ACTIVE NOT RECRUITING | 2029-10-26 | NCT05933577 |
| Regeneron | Fianlimab | — | ACTIVE NOT RECRUITING | 2026-03-12 | NCT05352672 |
| Pfizer | Encorafenib | — | ACTIVE NOT RECRUITING | 2026-01-12 | NCT04657991 |
| Biocad | BCD-263 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06640530 |
| Bristol-Myers Squibb | Nivolumab + Relatlimab | — | ACTIVE NOT RECRUITING | 2025-08-04 | NCT05625399 |
| IO Biotech | IO102-IO103 | — | ACTIVE NOT RECRUITING | 2025-05-30 | NCT05155254 |
| Philogen S.p.A. | L19IL2 + L19TNF | — | ACTIVE NOT RECRUITING | 2024-10 | NCT02938299 |
| Biocad | BCD-217 | — | ACTIVE NOT RECRUITING | 2024-06-20 | NCT05732805 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2022-06-28 | NCT04099251 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2021-06-21 | NCT03553836 |
| Bristol-Myers Squibb | Relatlimab | — | ACTIVE NOT RECRUITING | 2021-01-25 | NCT03470922 |
| Merck | pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2018-01-08 | NCT02362594 |
| Amgen | ABP 206 | — | COMPLETED | 2025-03-26 | NCT05907122 |
| Merck | Pembrolizumab/Vibostolimab | — | COMPLETED | 2024-03-06 | NCT05665595 |
| Bristol-Myers Squibb | Nivolumab/rHuPH20 | — | COMPLETED | 2024-02-08 | NCT05297565 |
| Delcath Systems Inc. | — | — | COMPLETED | 2023-05-18 | NCT02678572 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2023-01-18 | NCT03820986 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2023-01-18 | NCT04889118 |
| Bristol-Myers Squibb | NKTR-214 | — | COMPLETED | 2021-11-19 | NCT03635983 |
| Novartis | Dabrafenib | — | COMPLETED | 2020-10-05 | NCT03551626 |
| Bristol-Myers Squibb | BMS-986205 | — | COMPLETED | 2020-07-02 | NCT03329846 |
| Bristol-Myers Squibb | nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2020-06-12 | NCT03068455 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2020-02-10 | NCT02599402 |
| Roche | Atezolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2019-10-11 | NCT02908672 |
| Bristol-Myers Squibb | Ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | COMPLETED | 2019-04-19 | NCT02545075 |
| Bristol-Myers Squibb | Ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | COMPLETED | 2018-11-26 | NCT02388906 |
| Incyte Corporation | pembrolizumab + epacadostat | — | COMPLETED | 2018-01-08 | NCT02752074 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2017-10-23 | NCT02905266 |
| Novartis | Dabrafenib | — | COMPLETED | 2017-06-30 | NCT01682083 |
| Roche | Vemurafenib | Kinase Inhibitor [EPC] | COMPLETED | 2017-06-23 | NCT01667419 |
| Bristol-Myers Squibb | Nivolumab 3 mg/kg IV | — | COMPLETED | 2017-04-20 | NCT02714218 |
| Pfizer | LGX818 | — | COMPLETED | 2016-11-09 | NCT01909453 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2016-08-01 | NCT01844505 |
| Roche | Vemurafenib | Kinase Inhibitor [EPC] | COMPLETED | 2016-02-24 | NCT01307397 |
| Bristol-Myers Squibb | BMS-936558 | — | COMPLETED | 2016-02-16 | NCT01721746 |
| Bristol-Myers Squibb | Ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | COMPLETED | 2016-02-06 | NCT01515189 |
| Pfizer | MEK162 | — | COMPLETED | 2015-12-01 | NCT01763164 |
| AstraZeneca | 75mg selumetinib | — | COMPLETED | 2015-05 | NCT01974752 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2015-03-03 | NCT01866319 |
| BioVex Limited | Talimogene Laherparepvec | — | COMPLETED | 2014-09 | NCT01368276 |
| Bristol-Myers Squibb | BMS-936558 (Nivolumab) | — | COMPLETED | 2014-06-24 | NCT01721772 |
| Roche | Vemurafenib | Kinase Inhibitor [EPC] | COMPLETED | 2014-05-09 | NCT01689519 |
| Novartis | Dabrafenib | — | COMPLETED | 2014-04-17 | NCT01597908 |
| Novartis | Dabrafenib | — | COMPLETED | 2013-08-26 | NCT01584648 |
| Bristol-Myers Squibb | ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | COMPLETED | 2013-07-26 | NCT00636168 |
| BioVex Limited | Talimogene laherparepvec | — | COMPLETED | 2013-02 | NCT00769704 |
| Bristol-Myers Squibb | ABI-007 | — | COMPLETED | 2012-06-01 | NCT00864253 |
| GSK | GSK1120212 | — | COMPLETED | 2011-10-26 | NCT01245062 |
| Navidea Biopharmaceuticals | Lymphoseek | — | COMPLETED | 2011-04 | NCT01106040 |
| Roche | Vemurafenib | Kinase Inhibitor [EPC] | COMPLETED | 2010-12 | NCT01006980 |
| Navidea Biopharmaceuticals | Lymphoseek | — | COMPLETED | 2009-06 | NCT00671918 |
| Novartis | JPB898 (Induction and Maintenance) | — | TERMINATED | 2026-01-23 | NCT06587451 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | TERMINATED | 2024-12-16 | NCT05002569 |
| Regeneron | CMP-001 | — | TERMINATED | 2024-07-22 | NCT04695977 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI310+IBI308 | — | TERMINATED | 2023-02-28 | NCT04277663 |
| Nektar Therapeutics | Bempegaldesleukin | — | TERMINATED | 2022-09-22 | NCT04410445 |
| Idera Pharmaceuticals, Inc. | Ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | TERMINATED | 2021-06-01 | NCT03445533 |
| Polynoma LLC | POL-103A | — | TERMINATED | 2021-04-29 | NCT01546571 |
| Amgen | Talimogene Laherparepvec | — | TERMINATED | 2021-03-11 | NCT02263508 |
| Novartis | Spartalizumab | — | TERMINATED | 2020-08-11 | NCT02967692 |
| AB Science | Masitinib | — | TERMINATED | 2019-08 | NCT01280565 |
| Roche | Cobimetinib | — | TERMINATED | 2019-04-15 | NCT03273153 |
| Provectus Biopharmaceuticals, Inc. | PV-10 (10% rose bengal disodium) | — | TERMINATED | 2019-04 | NCT02288897 |
| GSK | GSK 2132231A | — | TERMINATED | 2016-01-27 | NCT00796445 |
| Lisata Therapeutics, Inc. | Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) | — | TERMINATED | 2016-01 | NCT01875653 |
| Eli Lilly | Tasisulam-sodium | — | TERMINATED | 2011-03 | NCT01006252 |
Showing 100 of 327 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Aulos Bioscience, Inc. | AU-007 | — | RECRUITING | 2026-06-12 | NCT05267626 |
| Medicenna Therapeutics, Inc. | MDNA11 | — | RECRUITING | 2026-06-30 | NCT05086692 |
| CJ Bioscience, Inc. | CJRB-101 | — | RECRUITING | 2026-07 | NCT05877430 |
| Shanghai Juncell Therapeutics | GC101 TIL | — | RECRUITING | 2026-07-10 | NCT06703398 |
| OncoResponse, Inc. | OR502 | — | RECRUITING | 2026-08-01 | NCT06090266 |
| ImmVira Pharma Co. Ltd | T3011 | — | RECRUITING | 2026-09-22 | NCT04370587 |
| Shanghai Pharmaceuticals Holding Co., Ltd | T3011 | — | RECRUITING | 2026-09-30 | NCT06214156 |
| Shanghai JMT-Bio Inc. | JMT108 | — | RECRUITING | 2026-11-30 | NCT07280832 |
| Georgiamune Inc | GIM-531 | — | RECRUITING | 2026-12 | NCT06425926 |
| Beijing Scitech-Mq Pharmaceuticals Limited | ST-1898 tablets | — | RECRUITING | 2026-12 | NCT06359860 |
| GV20 Therapeutics | GV20-0251 | — | RECRUITING | 2026-12-15 | NCT05669430 |
| Psyence Australia Pty Ltd | Psilocybin therapy | — | RECRUITING | 2026-12-30 | NCT07072728 |
| BioInvent International AB | BI-1808 | — | RECRUITING | 2026-12-31 | NCT04752826 |
| IDEAYA Biosciences | IDE196 | — | RECRUITING | 2027-01-29 | NCT03947385 |
| Neonc Technologies, Inc. | NEO212 Oral Capsule | — | RECRUITING | 2027-02-28 | NCT06047379 |
| Hummingbird Bioscience | ENV-501 | — | RECRUITING | 2027-07 | NCT06956690 |
| Krystal Biotech, Inc. | KB707 | — | RECRUITING | 2027-07 | NCT05970497 |
| GV20 Therapeutics | GV20-0251 | — | RECRUITING | 2027-07-16 | NCT07070518 |
| Daiichi Sankyo | HER3-DXd | — | RECRUITING | 2027-09-01 | NCT06172478 |
| Nanjing Leads Biolabs Co.,Ltd | LBL-024 for Injection | — | RECRUITING | 2027-10-30 | NCT07099430 |
| Toray Industries, Inc | TRK-950 | — | RECRUITING | 2027-12 | NCT05423262 |
| Suzhou BlueHorse Therapeutics Co., Ltd. | LM103 TILs Injection | — | RECRUITING | 2027-12-31 | NCT07310784 |
| Hangzhou Hanx Biopharmaceuticals, Ltd. | HX009+IN10018 | — | RECRUITING | 2027-12-31 | NCT06708663 |
| 7 Hills Pharma, LLC | Alintegimod | — | RECRUITING | 2027-12-31 | NCT06362369 |
| Perspective Therapeutics | [203Pb]VMT01 | — | RECRUITING | 2027-12-31 | NCT05655312 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | RECRUITING | 2028-02-02 | NCT02332668 |
| Aminex Therapeutics, Inc. | AMXT 1501 Dicaprate | — | RECRUITING | 2028-02-28 | NCT07287917 |
| Novelwise Pharmaceutical Corporation | NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. | — | RECRUITING | 2028-03-28 | NCT07136181 |
| Onchilles Pharma Inc | N17350 | — | RECRUITING | 2028-07 | NCT07339176 |
| Philogen S.p.A. | L19IL2 | — | RECRUITING | 2028-07 | NCT06284590 |
| Bristol-Myers Squibb | BMS-986340 | — | RECRUITING | 2028-07-07 | NCT04895709 |
| Merck | Intismeran autogene | — | RECRUITING | 2028-07-22 | NCT06961006 |
| Beijing Tide Pharmaceutical Co., Ltd | TCC1727 tablet 90mg | — | RECRUITING | 2028-09-30 | NCT07371663 |
| Obsidian Therapeutics, Inc. | OBX-115 | — | RECRUITING | 2029-06-30 | NCT06060613 |
| Hanmi Pharmaceutical Company Limited | Belvarafenib | — | RECRUITING | 2029-09 | NCT07449754 |
| AstraZeneca | AZD6750 | — | RECRUITING | 2029-10-02 | NCT07115043 |
| Regeneron | REGN10597 | — | RECRUITING | 2030-02-03 | NCT06413680 |
| Diakonos Oncology Corporation | DOC1021 | — | RECRUITING | 2031-01 | NCT07288112 |
| Iovance Biotherapeutics, Inc. | IOV-3001 | — | RECRUITING | 2032-06 | NCT06940739 |
| Multitude Therapeutics Inc. | AMT-253 for injection | — | RECRUITING | 2026-04-30 | NCT06209580 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI363 | — | RECRUITING | 2026-03-31 | NCT06797297 |
| Binhui Biopharmaceutical Co., Ltd. | OH2 injection | — | RECRUITING | 2026-03-13 | NCT04386967 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI363 | — | RECRUITING | 2026-03-01 | NCT06281678 |
| Innolake Biopharm | ILB-2109 | — | RECRUITING | 2026-01-25 | NCT05955105 |
| Rapa Therapeutics LLC | RAPA-201 Rapamycin Resistant T Cells | — | RECRUITING | 2026-01-01 | NCT05144698 |
| Binhui Biopharmaceutical Co., Ltd. | OH2 injection | — | RECRUITING | 2025-11-30 | NCT04616443 |
| GI Innovation, Inc. | GI-102 subcutaneous (SC) | — | RECRUITING | 2025-11-12 | NCT05824975 |
| Simcha IL-18, Inc. | ST-067 | — | RECRUITING | 2025-06-30 | NCT04787042 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI363 | — | RECRUITING | 2025-06-06 | NCT06081920 |
| Vyriad, Inc. | VV1 | — | RECRUITING | 2025-06 | NCT04291105 |
| Iovance Biotherapeutics, Inc. | IOV-4001 | — | RECRUITING | 2025-06 | NCT05361174 |
| GeneMedicine Co., Ltd. | GM103 (Part A) | — | RECRUITING | 2025-05-30 | NCT06265025 |
| Zhuhai Yufan Biotechnologies Co., Ltd | PRJ1-3024 | — | RECRUITING | 2025-04-30 | NCT06727630 |
| IO Biotech | IO102-IO103 | — | RECRUITING | 2025-04-30 | NCT05280314 |
| DermBiont, Inc. | SM-020 1% Gel | — | RECRUITING | 2024-11 | NCT06409195 |
| Immuneering Corporation | IMM-1-104 Monotherapy (Treatment Group A) | — | ACTIVE NOT RECRUITING | 2026-06 | NCT05585320 |
| OncoC4, Inc. | ONC-392 | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT04140526 |
| GSK | Cobolimab | — | ACTIVE NOT RECRUITING | 2026-10-13 | NCT06521567 |
| Inhibrx Biosciences, Inc | INBRX-106 - Hexavalent OX40 agonist antibody | — | ACTIVE NOT RECRUITING | 2026-10-30 | NCT04198766 |
| Regeneron | cemiplimab | — | ACTIVE NOT RECRUITING | 2026-11-02 | NCT06190951 |
| Sapience Therapeutics | ST101 | — | ACTIVE NOT RECRUITING | 2026-12 | NCT04478279 |
| Scancell Ltd | SCIB1 or iSCIB1+ DNA vaccine | — | ACTIVE NOT RECRUITING | 2027-01-31 | NCT04079166 |
| Novartis | LXH254 | — | ACTIVE NOT RECRUITING | 2027-02-02 | NCT04417621 |
| IDEAYA Biosciences | Darovasertib | — | ACTIVE NOT RECRUITING | 2027-04-30 | NCT05907954 |
| Sensei Biotherapeutics, Inc. | SNS-101 (anti-VISTA) | — | ACTIVE NOT RECRUITING | 2027-06 | NCT05864144 |
| Roche | RO7247669 | — | ACTIVE NOT RECRUITING | 2027-06-30 | NCT04140500 |
| Genmab | Acasunlimab | — | ACTIVE NOT RECRUITING | 2027-07-15 | NCT06984328 |
| Ascendis Pharma Oncology Division A/S | TransCon IL-2 β/γ | — | ACTIVE NOT RECRUITING | 2027-08 | NCT05081609 |
| Novartis | DYP688 | — | ACTIVE NOT RECRUITING | 2027-10-01 | NCT05415072 |
| iOnctura | roginolisib | — | ACTIVE NOT RECRUITING | 2027-12 | NCT06717126 |
| Agenus Inc. | Botensilimab | — | ACTIVE NOT RECRUITING | 2028-02 | NCT05529316 |
| Ipsen | IPN01194 | — | ACTIVE NOT RECRUITING | 2028-03-20 | NCT06305247 |
| Replimune, Inc. | RP1 | — | ACTIVE NOT RECRUITING | 2028-06 | NCT03767348 |
| ImmunityBio, Inc. | N-803 + Pembrolizumab | — | ACTIVE NOT RECRUITING | 2029-08-31 | NCT03228667 |
| ModernaTX, Inc. | mRNA-4157 | — | ACTIVE NOT RECRUITING | 2032-11-30 | NCT03897881 |
| Iovance Biotherapeutics, Inc. | Lifileucel | — | ACTIVE NOT RECRUITING | 2032-12 | NCT07288203 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2026-05-20 | NCT04305054 |
| Roche | Entrectinib | ALK/ROS1/NTRK1/TRKB/TRKC | ACTIVE NOT RECRUITING | 2026-05-14 | NCT02568267 |
| ENB Therapeutics, Inc | ENB003 | — | ACTIVE NOT RECRUITING | 2026-01-01 | NCT04205227 |
| Genmab | GEN1042 | — | ACTIVE NOT RECRUITING | 2025-12-30 | NCT04083599 |
| BioInvent International AB | pembrolizumab (KEYTRUDA®) | — | ACTIVE NOT RECRUITING | 2025-12-30 | NCT06784648 |
| Ascentage Pharma Group Inc. | Phase 1b: APG-115+pembrolizumab | — | ACTIVE NOT RECRUITING | 2025-12-30 | NCT03611868 |
| Salubris Biotherapeutics Inc | JK08 | — | ACTIVE NOT RECRUITING | 2025-10-17 | NCT05620134 |
| Evaxion Biotech A/S | EVX-01 | — | ACTIVE NOT RECRUITING | 2025-09-30 | NCT05309421 |
| ImaginAb, Inc. | zirconium Zr 89 crefmirlimab berdoxam | — | ACTIVE NOT RECRUITING | 2025-07 | NCT05013099 |
| BeiGene | BGB-A445 | — | ACTIVE NOT RECRUITING | 2025-05-27 | NCT05661955 |
| Bristol-Myers Squibb | relatlimab+nivolumab | — | ACTIVE NOT RECRUITING | 2025-04-10 | NCT06101134 |
| Merck | Pembrolizumab (+) Berahyaluronidase alfa | — | ACTIVE NOT RECRUITING | 2025-04-09 | NCT06099782 |
| BioAtla, Inc. | BA3071 | — | ACTIVE NOT RECRUITING | 2025-03-19 | NCT05180799 |
| NGM Biopharmaceuticals, Inc | NGM707 | — | ACTIVE NOT RECRUITING | 2025-02 | NCT04913337 |
| iTeos Belgium SA | EOS-448 | — | ACTIVE NOT RECRUITING | 2024-07 | NCT05060432 |
| AstraZeneca | Ceralasertib | — | ACTIVE NOT RECRUITING | 2024-04-12 | NCT05061134 |
| AstraZeneca | Trastuzumab deruxtecan | — | ACTIVE NOT RECRUITING | 2023-01-25 | NCT04639219 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQB2916 injection + doxorubicin hydrochloride for injection | — | NOT YET RECRUITING | 2026-06 | NCT06500091 |
| Second Life Therapeutics | SL-28 | — | NOT YET RECRUITING | 2027-01-01 | NCT07341737 |
| Oncodesign Precision Medicine | OPM-101 | — | NOT YET RECRUITING | 2027-09 | NCT07040436 |
| Primmune Therapeutics, Inc. | PRTX007 | — | NOT YET RECRUITING | 2027-12 | NCT07565285 |
| Xynomic Pharmaceuticals, Inc. | XP-102 | — | NOT YET RECRUITING | 2027-12-30 | NCT05275374 |
| Qingdao Sino-Cell Biomedicine Co., Ltd. | Lymphodepletion Conditioning | — | NOT YET RECRUITING | 2027-12-31 | NCT07406724 |
| Rapa Therapeutics LLC | RAPA-201 Rapamycin Resistant T Cells | — | NOT YET RECRUITING | 2029-03-01 | NCT06708455 |
Showing 100 of 303 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Chiome Bioscience Inc. | CBA-1205 Part 1 | — | RECRUITING | 2026-06-30 | NCT06636435 |
| Nurix Therapeutics, Inc. | NX-1607 | — | RECRUITING | 2026-08-31 | NCT05107674 |
| Adze Biotechnology Australia Pty Ltd | Adze1.C | — | RECRUITING | 2026-11-30 | NCT07086105 |
| Compass Therapeutics | CTX-8371 | — | RECRUITING | 2026-12 | NCT06150664 |
| ViroMissile, Inc. | IDOV-Immune (oncolytic vaccinia virus) | — | RECRUITING | 2027-01-31 | NCT06910657 |
| Memgen, Inc. | MEM-288 Intratumoral Injection | — | RECRUITING | 2027-02 | NCT05076760 |
| MonTa Biosciences ApS | MBS8(1V270) | — | RECRUITING | 2027-03 | NCT04855435 |
| Y-mAbs Therapeutics | GD2-SADA:177Lu-DOTA Complex | — | RECRUITING | 2027-03 | NCT05130255 |
| Guangzhou FineImmune Biotechnology Co., LTD. | Super1 TCR-T | — | RECRUITING | 2027-04-25 | NCT06942143 |
| Valo Therapeutics Oy | PeptiCRAd-1 | — | RECRUITING | 2027-04-30 | NCT05492682 |
| Shanghai Henlius Biotech | HLX17 | — | RECRUITING | 2027-04-30 | NCT07160335 |
| Rise Therapeutics LLC | R-5780 | — | RECRUITING | 2027-04-30 | NCT06398418 |
| Pfizer | PF-07799544 | — | RECRUITING | 2027-08-09 | NCT05538130 |
| Novelty Nobility, Inc. | NN3201 | — | RECRUITING | 2027-08-30 | NCT06805825 |
| KaliVir Immunotherapeutics | VET3-TGI | — | RECRUITING | 2027-09-30 | NCT06444815 |
| LG Chem | Phase 1a: LB-LR1109 | — | RECRUITING | 2027-11 | NCT06332755 |
| Relay Therapeutics, Inc. | RLY-8161 | — | RECRUITING | 2027-12-30 | NCT07584226 |
| Alpha-9 Oncology USA Inc. | [225Ac]Ac-A9-3408 | — | RECRUITING | 2028-01 | NCT07076550 |
| MacroGenics | MGC026 Dose Escalation | — | RECRUITING | 2028-05 | NCT06242470 |
| Pfizer | PF-08046033 | — | RECRUITING | 2028-07-14 | NCT07519655 |
| Roche | Enzelkitug | — | RECRUITING | 2028-07-31 | NCT05581004 |
| Nested Therapeutics, Inc | NST-628 | — | RECRUITING | 2028-11 | NCT06326411 |
| Kupando GmbH | KUP-101A | — | RECRUITING | 2028-12 | NCT07600476 |
| Pfizer | PF-07799933 | — | RECRUITING | 2029-02-02 | NCT05355701 |
| Immatics US, Inc. | IMA203 | — | RECRUITING | 2029-08 | NCT06946225 |
| Boehringer Ingelheim | BI 3810944 | — | RECRUITING | 2029-10-05 | NCT07224425 |
| Hangzhou DAC Biotechnology Co., Ltd. | DXC014 | — | RECRUITING | 2030-10-20 | NCT07177937 |
| OncoNano Medicine, Inc. | ONM-501 | — | RECRUITING | 2026-04-30 | NCT06022029 |
| Shandong Boan Biotechnology Co., Ltd | BA1302 | — | RECRUITING | 2025-12-31 | NCT06596915 |
| BioEclipse Therapeutics | CRX100 suspension for infusion | — | RECRUITING | 2025-08 | NCT04282044 |
| Suzhou BlueHorse Therapeutics Co., Ltd. | Autologous tumor infiltrating lymphocytes (TILs) | — | RECRUITING | 2024-05-30 | NCT05366478 |
| Aivita Biomedical, Inc. | AV-MEL-1 | — | RECRUITING | 2024-05 | NCT03743298 |
| Boehringer Ingelheim | BI 765063 | — | ACTIVE NOT RECRUITING | 2026-05-29 | NCT05068102 |
| Novartis | GME751 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT06153238 |
| Toray Industries, Inc | TRK-950 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT03872947 |
| Seagen, a wholly owned subsidiary of Pfizer | PF-08046049 | — | ACTIVE NOT RECRUITING | 2026-06-06 | NCT05571839 |
| Formycon AG | FYB206 | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT06551064 |
| Iovance Biotherapeutics, Inc. | LN-145/LN-144 | — | ACTIVE NOT RECRUITING | 2026-07 | NCT06566092 |
| OncoC4, Inc. | AI-061 | — | ACTIVE NOT RECRUITING | 2026-07-31 | NCT05858736 |
| Syntrix Biosystems, Inc. | SX-682 | — | ACTIVE NOT RECRUITING | 2026-08 | NCT03161431 |
| Asher Biotherapeutics, Inc. | etakafusp alfa (AB248) | — | ACTIVE NOT RECRUITING | 2026-08 | NCT05653882 |
| Novartis | DKY709 | — | ACTIVE NOT RECRUITING | 2026-10-30 | NCT03891953 |
| TILT Biotherapeutics Ltd. | TILT-123 | — | ACTIVE NOT RECRUITING | 2026-11 | NCT06961786 |
| HiFiBiO Therapeutics | HFB200301 | — | ACTIVE NOT RECRUITING | 2026-12 | NCT05238883 |
| TILT Biotherapeutics Ltd. | TILT-123 | — | ACTIVE NOT RECRUITING | 2026-12 | NCT05222932 |
| USWM CT, LLC | — | — | ACTIVE NOT RECRUITING | 2026-12-23 | NCT04044859 |
| TScan Therapeutics, Inc. | TSC-204-A0201 | — | ACTIVE NOT RECRUITING | 2026-12-30 | NCT05973487 |
| AgonOx, Inc. | DP CD8 TIL | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05902520 |
| NeoTX Therapeutics Ltd. | — | — | ACTIVE NOT RECRUITING | 2027-03-01 | NCT03983954 |
| Modulation Therapeutics, Inc. | 4.7 microCi 225Ac-MTI-201 | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT05496686 |
| Nanobiotix | NBTXR3 | — | ACTIVE NOT RECRUITING | 2027-04-30 | NCT03589339 |
| Roche | Belvarafenib | — | ACTIVE NOT RECRUITING | 2027-06-30 | NCT04835805 |
| Novartis | KFA115 | — | ACTIVE NOT RECRUITING | 2027-09-01 | NCT05544929 |
| Pierre Fabre Medicament | KIN-2787 | — | ACTIVE NOT RECRUITING | 2028-11-30 | NCT04913285 |
| Phio Pharmaceuticals Inc. | PH-762 | — | ACTIVE NOT RECRUITING | 2025-12-29 | NCT06014086 |
| HiFiBiO Therapeutics | HFB200603 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05789069 |
| Microbiotica Ltd | MB097 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06540391 |
| Theratechnologies | TH1902 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT04706962 |
| NGM Biopharmaceuticals, Inc | NGM831 | — | ACTIVE NOT RECRUITING | 2025-07 | NCT05215574 |
| RemeGen Co., Ltd. | RC198 Injection | — | ACTIVE NOT RECRUITING | 2024-09-30 | NCT05867303 |
| Biomica Ltd. | BMC128 | — | ACTIVE NOT RECRUITING | 2024-05 | NCT05354102 |
| Biocad | BCD-263 | — | ACTIVE NOT RECRUITING | 2024-01-31 | NCT06112808 |
| iOnctura | IOA-244 | — | ACTIVE NOT RECRUITING | 2023-12-13 | NCT04328844 |
| USWM CT, LLC | — | — | ACTIVE NOT RECRUITING | 2022-12-27 | NCT03132922 |
| Checkpoint Therapeutics, Inc. | CK-301 (cosibelimab) | — | ACTIVE NOT RECRUITING | 2021-11-18 | NCT03212404 |
| Biotroy Therapeutics | BT02 | — | NOT YET RECRUITING | 2027-05 | NCT07107178 |
| AccSalus Biosciences, Inc. | ACC-1898 | — | NOT YET RECRUITING | 2027-06 | NCT07252661 |
| Shanghai Henlius Biotech | HLX18 | — | NOT YET RECRUITING | 2027-08-12 | NCT07518043 |
| Biocon Biologics UK PLC | Bmab1700 | — | NOT YET RECRUITING | 2027-08-16 | NCT07476326 |
| Alvotech Swiss AG | AVT32-DRL_PB | — | NOT YET RECRUITING | 2027-10 | NCT07475572 |
| Biocon Biologics UK PLC | Bmab1800 | — | NOT YET RECRUITING | 2027-12-15 | NCT07581509 |
| C4 Therapeutics, Inc. | CFT1946 | — | COMPLETED | 2025-11-05 | NCT05668585 |
| Arcus Biosciences, Inc. | AB308 | — | COMPLETED | 2025-08-25 | NCT04772989 |
| Roche | Autogene cevumeran | — | COMPLETED | 2025-07-01 | NCT03289962 |
| MacroGenics | vobramitamab duocarmazine | — | COMPLETED | 2025-06-24 | NCT05293496 |
| Compass Therapeutics | CTX-471 | — | COMPLETED | 2025-05-21 | NCT03881488 |
| Xencor, Inc. | XmAb®808 | — | COMPLETED | 2025-05-20 | NCT05585034 |
| NantBioScience, Inc. | YE-NEO-001 | — | COMPLETED | 2025-03-18 | NCT03552718 |
| InxMed (Shanghai) Co., Ltd. | IN10018 | — | COMPLETED | 2024-12-20 | NCT04109456 |
| Bio-Thera Solutions | BAT4706 | — | COMPLETED | 2024-11-05 | NCT05148325 |
| AstraZeneca | AZD8701 | — | COMPLETED | 2024-10-07 | NCT04504669 |
| MacroGenics | Lorigerlimab | — | COMPLETED | 2024-08-29 | NCT03761017 |
| Nanjing Leads Biolabs Co.,Ltd | LBL-007 | — | COMPLETED | 2024-08-19 | NCT04640545 |
| invoX Pharma Limited | SB 11285 | — | COMPLETED | 2024-07-16 | NCT04096638 |
| Roche | Lomvastomig | — | COMPLETED | 2024-07-09 | NCT03708328 |
| Tvardi Therapeutics, Incorporated | TTI-101 | — | COMPLETED | 2024-06-24 | NCT03195699 |
| Gene Surgery LLC | Stimotimagene copolymerplasmid | — | COMPLETED | 2024-04-11 | NCT05578820 |
| Xencor, Inc. | XmAb®23104 | — | COMPLETED | 2024-02-15 | NCT03752398 |
| TILT Biotherapeutics Ltd. | TILT-123 | — | COMPLETED | 2023-12-12 | NCT04217473 |
| Merck | Pembrolizumab Dose C | — | COMPLETED | 2023-12-04 | NCT03665597 |
| TuHURA Biosciences, Inc. | IFx-Hu2.0 | — | COMPLETED | 2023-10-19 | NCT04160065 |
| Cantargia AB | CAN04 | — | COMPLETED | 2023-06-28 | NCT04452214 |
| BioNTech SE | Lipo-MERIT | — | COMPLETED | 2023-06-20 | NCT02410733 |
| Shattuck Labs, Inc. | SL-279252 | — | COMPLETED | 2023-05-04 | NCT03894618 |
| Xencor, Inc. | XmAb®22841 | — | COMPLETED | 2023-02-16 | NCT03849469 |
| Prelude Therapeutics | PRT1419 | — | COMPLETED | 2023-02-06 | NCT04837677 |
| Pierre Fabre Medicament | Binimetinib 15 MG | — | COMPLETED | 2022-12-22 | NCT05810740 |
| Regeneron | CMP-001 | — | COMPLETED | 2022-12-06 | NCT02680184 |
| Fate Therapeutics | FT500 | — | COMPLETED | 2022-11-15 | NCT03841110 |
| Ultimovacs ASA | UV1 | — | COMPLETED | 2022-10-01 | NCT03538314 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Melanoma
Novel Drugs by Company (New molecular entities)
Reformulations (3 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Generic Drugs (1 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs